MannKind initiated with an Outperform at SVB Leerink. SVB Leerink analyst Pasha Sarraf initiated MannKind with an Outperform rating and $3 price target, telling investors in a research note that this is a “do or die” year for the company. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
https://thefly.com/landingPageNews.php?id=2868725
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.